Related Experiment Video
Updated: Jan 22, 2026

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
Published on: August 21, 2019
[Role of STAT3 in Resistance of Non-small Cell Lung Cancer]
Sibo Sun1, Shidai Jin1, Renhua Guo1
1Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Abstract:
The inflammatory state of tumor microenvironment play an important role in non-small cell lung cancer (NSCLC) drug resistance. As the key signal pathway connecting inflammation and tumor, activated signal transduction and transcriptional activation factor 3 (STAT3) leads togenetic abnormal expression, gene silencing, genomic instability, etc. in tumor cells, and induces therapeutic resistance. STAT3 has thepotential to be a new target for reversal of resistance. In this review, we summarize the progress of STAT3 in acquired drug resistance of NSCLC, explore the possibility of STAT3 as a new target to reverse drug resistance, and provide basic theories for the new clinical treatment strategy of acquired drug resistance in NSCLC. .
Insights
The inflammatory tumor microenvironment drives non-small cell lung cancer (NSCLC) drug resistance. Targeting signal transducer and activator of transcription 3 (STAT3) may reverse this resistance, offering new therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- The tumor microenvironment's inflammatory state is crucial in non-small cell lung cancer (NSCLC) drug resistance.
- Signal transducer and activator of transcription 3 (STAT3) is a key pathway linking inflammation and tumor progression.
- Activated STAT3 contributes to genetic instability and therapeutic resistance in cancer cells.
Purpose of the Study:
- To review the role of STAT3 in acquired drug resistance in NSCLC.
- To explore STAT3 as a potential therapeutic target for overcoming drug resistance.
- To provide a theoretical basis for novel clinical strategies against NSCLC drug resistance.
Main Methods:
- Literature review of studies on STAT3 and NSCLC drug resistance.
- Analysis of the molecular mechanisms by which STAT3 influences therapeutic resistance.
- Synthesis of current research to identify STAT3 as a target.
Main Results:
- STAT3 activation is implicated in various resistance mechanisms in NSCLC.
- Targeting STAT3 demonstrates potential for reversing acquired drug resistance.
- Understanding STAT3's role offers insights into overcoming treatment failure.
Conclusions:
- STAT3 is a significant factor in NSCLC acquired drug resistance.
- STAT3 inhibition presents a promising strategy for enhancing NSCLC treatment efficacy.
- Further research into STAT3-targeted therapies is warranted for clinical application.
Related Concept Videos
Treatment Resistant Cancers
Role of Myosin in Cell Migration
Myosin II is a hexamer comprising two heavy chains with globular heads and coiled-coil tails, two regulatory light chains, and two essential light chains. The ATPase sites on the myosin heads hydrolyze ATP, and the released phosphate generates the force for contraction....
Lung Capacity
Role of Microtubules in Cell Wall Deposition
The Role of Actin and Myosin in Non-muscle Cells
Resistivity

